IMCR Q3 2025 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104M+29.2% YoY

Gross Profit

$103M99.5% margin

Operating Income

-$7M-6.9% margin

Net Income

$785,0000.8% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$706M

Stockholders' Equity

$397M

Cash & Equivalents

$498M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$80M	+29.2%
Gross Profit	$103M	$80M	+29.3%
Operating Income	-$7M	-$9M	+15.7%
Net Income	$785,000	$9M	-91.0%

Revenue Segments

Sale of Therapies

$104M100%

Geographic Segments

UNITED STATES

$67M65%

Europe

$34M32%

Rest of World

$3M3%